在黑色素瘤中应用免疫组化方法检测BRAF V600E突变

北京大学肿瘤医院病理科

刘卉

2014 年 3 月 26日

Homogeneity and heterogeneity

Detection comparison

Three technical problems

参考文献1. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med.

2011; 364(26):2507-2516.2. Sosman JA, Kim KB, Schucher L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;

366(8): 707-714.3. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949–9544. Capper D, Berghoff AS, Magerle M, et al. Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients

with brain metastases. Acta Neuropathol. 2012; 123(2): 223-233.5. Koperek O, Kornauth C, Capper D, et al. Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid

carcinoma. Am J Surg Pathol. 2012; 36(6):844-850.6. Long GV, Wilmott JS, Capper D, et al. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in

melanoma. Am J Surg Pathol. 2013; 37(1): 61-65.7. Ilie M, Long E, Hofman V, et al. Diagnostic value of immunohistochemistry for the detection of the BRAFV600E mutation in primary lung

adenocarcinoma Caucasian patients. Annals of oncology, 2013, 24(3): 742-748.8. Bösmüller H, Fischer A, Pham DL, et al. Detection of the< i> BRAF</i> V600E mutation in serous ovarian tumors: a comparative analysis of

immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR. Human pathology, 2013, 44(3): 329-335.9. Adackapara CA, Sholl LM, Barletta JA, et al. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is

not a useful surrogate for genotyping in colorectal adenocarcinoma. Histopathology. 2013 63(2): 187-93.10. Tan Y H, Liu Y, Eu K W, et al. Detection of BRAF V600E mutation by pyrosequencing. Pathology, 2008, 40(3): 295-298.11. Capper D, Preusser M, Habel A, et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific

monoclonal antibody. Acta neuropathologica, 2011, 122(1): 11-19.12. Boursault L, Haddad V, Vergier B, et al. Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma

determined by immunohistochemical and molecular testing. PloS one, 2013, 8(8): e70826.13. Routhier CA, Mochel MC, Lynch K, et al. Comparison of 2 monoclonal antibodies for immunohistochemical detection of< i> BRAF</i>

V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas. Human pathology, 2013, 44(11): 2563-2570.

14. Busam K J, Hedvat C, Pulitzer M, et al. Immunohistochemical analysis of BRAFV600E expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions. Test Site, 2013, 37(3): 413-420.

谢谢！